{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:32Z","timestamp":1790821952850,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40265-024-02017-4","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T23:02:10Z","timestamp":1710284530000},"page":"479-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Fidanacogene Elaparvovec: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"2017_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2147\/TACG.S288256","volume":"14","author":"CH Miller","year":"2021","unstructured":"Miller CH. The clinical genetics of hemophilia B (factor IX deficiency). Appl Clin Genet. 2021;14:445\u201354.","journal-title":"Appl Clin Genet"},{"key":"2017_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","volume":"74","author":"BJ Samelson-Jones","year":"2023","unstructured":"Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74:231\u201347.","journal-title":"Annu Rev Med"},{"issue":"Suppl 6","key":"2017_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"23","key":"2017_CR4","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"2017_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342\u20137.","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"2017_CR6","first-page":"010","volume":"13","author":"P Monahan","year":"2015","unstructured":"Monahan P, Walsh C, Powell J, et al. Update on a phase 1\/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B [abstract no. LB010]. J Thromb Haemost. 2015;13(Suppl 2):010.","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2017_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994\u20132004.","journal-title":"N Engl J Med"},{"issue":"10","key":"2017_CR8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","volume":"125","author":"JM Crudele","year":"2015","unstructured":"Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood. 2015;125(10):1553\u201361.","journal-title":"Blood"},{"key":"2017_CR9","unstructured":"Pfizer Canada ULC. PrBEQVEZTM (fidanacogene elaparvovec): Canadian prescribing information 2023. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=103268. Accessed 8 Jan 2024."},{"key":"2017_CR10","unstructured":"Spark Therapeutics. Spark Therapeutics Launched with $50 Million in Financing to Advance Late- and Mid-Stage Gene Therapy Programs with Clinical Proof of Concept [media release]. https:\/\/www.prnewswire.com\/news-releases\/spark-therapeutics-launched-with-50-million-in-financing-to-advance-late--and-mid-stage-gene-therapy-programs-with-clinical-proof-of-concept-228752221.html. Accessed 22 Oct 2013."},{"key":"2017_CR11","unstructured":"Spark Therapeutics. Amedment to form S-1. 2015. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1609351\/000119312515013888\/d776249ds1a.htm. Accessed 28 Jan 2024."},{"key":"2017_CR12","unstructured":"Pfizer. Spark Therapeutics and Pfizer announce that SPK-9001, an investigational hemophilia B Medicine, has been granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency [media release]. https:\/\/sparktx.com\/press_releases\/spark-therapeutics-and-pfizer-amend-license-agreement-for-investigational-spk-9001-in-hemophilia-b\/. Accessed 1 Mar 2017."},{"key":"2017_CR13","unstructured":"Spark Therapeutics. Spark Therapeutics reports 2017 financial results and recent business progress. 2018. https:\/\/sparktx.com\/press_releases\/spark-therapeutics-reports-2017-financial-results-and-recent-business-progress\/. Accessed 28 Jan 2024."},{"key":"2017_CR14","unstructured":"Roche. Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy [media release]. https:\/\/www.roche.com\/media\/releases\/med-cor-2019-12-17b. Accessed 17 Dec 2019."},{"issue":"Suppl 1","key":"2017_CR15","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1182\/blood-2019-124091","volume":"134","author":"LA George","year":"2019","unstructured":"George LA, Sullivan SK, Rasko JEJ, et al. Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year [abstract no. 3347]. Blood. 2019;134(Suppl 1):3347.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2017_CR16","first-page":"124","volume":"30","author":"L Frenzel","year":"2024","unstructured":"Frenzel L, Alzahrani H, Cuker A, et al. Vector clearance following administration of fidanacogene elaparvovec gene therapy in adults with haemophilia B [abstract no. PO132]. Haemophilia. 2024;30(Suppl 1):124\u20135.","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"2017_CR17","first-page":"124","volume":"7","author":"A Cuker","year":"2023","unstructured":"Cuker A, Alzahrani H, Astermark J, et al. Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or svere hemophilia B: results from the phase 3 BENEGENE-2 gene therapy trial [abstract no. OC 52.3]. Res Pract Thromb Haemost. 2023;7(Suppl 2):124\u20135.","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"2017_CR18","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2023-181223","volume":"142","author":"L Frenzel","year":"2023","unstructured":"Frenzel L, Kavakli K, Klamroth R, et al. Characterizing a cohort of patients with hemophilia B treated with fidanacogene elaparvovec from the phase 3 BENEGENE-2 study who returned to factor IX prophylaxis. Blood. 2023;142(Suppl 1):2257.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2017_CR19","first-page":"92","volume":"30","author":"S von Mackensen","year":"2024","unstructured":"von Mackensen S, Bagot CN, Lienhart A, et al. Health-related quality of life in adults with haemophilia B after gene therapy with fidanacogene elaparvovec in the BENEGENE-2 trial [abstract no. PO116]. Haemophilia. 2024;30(Suppl 1):92.","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"2017_CR20","first-page":"113","volume":"29","author":"JEJ Rasko","year":"2023","unstructured":"Rasko JEJ, Chhabra A, Ducore JM, et al. Patterns of joint bleeds in patients with hemophilia B following fidanacogene elaparvovec adeno-associated virus gene therapy. Haemophilia. 2023;29(Suppl 1):113\u20134.","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"2017_CR21","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1182\/blood-2021-150541","volume":"138","author":"BJ Samelson-Jones","year":"2021","unstructured":"Samelson-Jones BJ, Sullivan SK, Rasko JEJ, et al. Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy. Blood. 2021;138(Suppl 1):3975.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2017_CR22","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1182\/blood-2023-179431","volume":"142","author":"S von Mackensen","year":"2023","unstructured":"von Mackensen S, Ducore JM, George LA, et al. Health-related quality of life in adults with hemophilia B after receiving gene therapy with fidanacogene elaparvovec. Blood. 2023;142(Suppl 1):3628.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02017-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:39:22Z","timestamp":1716003562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02017-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2017"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02017-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"28 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}